Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis

Hu Li, Nan-Nan Liu, Zong-Gen Peng

ABSTRACT

Objective Non-alcoholic fatty liver disease (NAFLD) is a global epidemic without effective therapeutic agents in the clinic. This meta-analysis aimed to assess the efficacy of the marketed hepatoprotectant bicyclol at improving blood biomarkers in patients with NAFLD.

Design Electronic databases were searched for randomised controlled trials (RCTs) published up to August 2020 using bicyclol to treat NAFLD. The risk of bias, quality of evidence and publication bias were evaluated. Blood biomarkers, including alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), triglyceride (TG) and total cholesterol (TC), were analysed using Review Manager V.5.3 software. Outcomes with significant heterogeneity (I² ≥75%) were divided into the bicyclol monotherapy subgroup and combination treatment subgroup.

Results Twelve RCTs involving 1008 patients were finally included. No serious adverse events were reported in the bicyclol-treated groups. The total effective rate of bicyclol intervention for NAFLD was significantly higher than that of the control group. The decreases in the levels of AST (mean difference (MD) = −15.20; 95% CI −20.51 to −9.90; I²=74%), TBIL (MD = −1.72; 95% CI −2.72 to −0.72; I²=0%) and TC (MD = −0.52; 95% CI −0.70 to −0.34; I²=67%) treated by bicyclol were significantly higher than those in the control group. When a high heterogeneity existed (I² ≥75%), subgroup analyses were conducted and revealed significantly decreased ALT levels (MD = −34.07; 95% CI −36.70 to −31.43; I²=0%) merely in the bicyclol monotherapy subgroup, while TG level (MD = −0.39; 95% CI −0.45 to −0.33; I²=0%) was decreased in the bicyclol combination therapy subgroup.

Conclusions The study presents the evidence of bicyclol monotherapy and/or combination therapy for improving liver function and blood lipid biomarkers in patients with NAFLD. This preliminary study predicts that bicyclol might be an alternative drug for NAFLD therapy in the future.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is the most common spectrum of liver diseases typically ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH).1 Benign and reversible NAFL is merely characterised by excessive lipid droplet deposition in hepatocytes, while NASH is a more aggressive condition characterised by inflammatory infiltrates, visible cellular injury and possible progression to, or accompanied by, fibrosis and cirrhosis.2 NAFLD is closely related to the high incidence of metabolic syndrome, cardiovascular disease, type 2 diabetes mellitus (T2DM) and advanced liver diseases.3–5 Currently, the prevalence of NAFLD worldwide is up to 25%, with the highest prevalence of 32% reported in the Middle East and 31% in South America, and even the lowest prevalence in Africa was estimated to be 14%.4 Worse still, the prevalence of NAFLD worldwide is presumed to be increasing.5 There are no admitted therapeutic agents from international societies for treating NAFLD, except for lifestyle changes.6–8 However, patients tend to exhibit poor adherence to this important intervention.9 Recently, only one dual peroxisome proliferator-activated receptor-α/γ agonist saroglitazar magnesium has been approved for the treatment of NASH without cirrhosis in India.10 However, numerous potential agents, such as farnesoid X receptor agonists, apoptosis signal-regulated kinase 1 inhibitors and C-C chemokine receptor type 2/5 inhibitors, have entered different phases in clinical trials but presented limited or even no benefits.11–12 Therefore, new or complementary drugs for treating NAFLD are still urgently needed and this dilemma might persist for a long time.
Bicyclol, a hepatoprotective and anti-inflammatory drug that has been approved in China since 2004, was used to treat increased levels of aminotransferases caused by various forms of chronic hepatitis mainly in Asian countries, while it has not been approved in Europe and North America.\textsuperscript{13}\textsuperscript{-15} It is rather safe and suitable for long-term (more than 6 months) oral administration.\textsuperscript{13} Many preclinical animal experiments have confirmed its therapeutic effect in chemical-induced, immunological, fatty and drug-induced liver injury, as well as hepatic fibrosis caused by bile duct ligation, dimethylnitrosamine, bovine serum albumin or carbon tetrachloride.\textsuperscript{13-15}\textsuperscript{13} The detailed mechanisms of bicyclol involve the inhibition of hepatic cyto apoptosis, stabilisation of mitochondrial or hepatic cyto membranes, scavenging free radicals, increasing the expression of antioxidant genes and reducing lipid peroxide levels.\textsuperscript{14}\textsuperscript{-16} Although liver histology and MRI have high accuracy for evaluating the liver fat content,\textsuperscript{17} liver function and blood lipid biomarkers, which mainly include alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), triglyceride (TG) and total cholesterol (TC), are commonly used to evaluate the severity of NAFLD and the subsequent abnormal metabolism.\textsuperscript{18,19}\textsuperscript{18,19} Relevant clinical and preclinical studies have reported the potential therapeutic role of bicyclol in NAFLD,\textsuperscript{20,21}\textsuperscript{20,21} however, its effect on non-invasive blood biomarkers in patients with NAFLD has not been precisely confirmed due to insufficient sample sizes and the low quality of studies. Hence, this meta-analysis aimed to evidence the effect of bicyclol on blood biomarker levels in patients with NAFLD through synthesising the clinical data using bicyclol monotherapy alone or in combination with other drugs to treat NAFLD, and to preliminarily predict its clinical efficacy in the future.

METHODS
The data included in this meta-analysis were derived from previously published clinical studies, all of which were conducted in China. The study protocol was confirmed by all authors before data collection. Our protocol has been registered at the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY). The registration number is INPLASY202080017 (DOI number is 10.37766/inplasy2020.8.0017, https://inplasy.com/inplasy-2020-8-0017/). We used analytical methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions\textsuperscript{25} and reported this study following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.\textsuperscript{23}

Search strategy
Studies up to August 2020 were searched in PubMed, Embase, Cochrane Library and Chinese databases, including the China National Knowledge Infrastructure database, the WeiPu (VIP)-Chinese scientific and technological journal database, and the Wanfang digital periodical full-text database. Search terms were (‘Non alcoholic Fatty Liver Disease’ OR ‘NAFLD’ OR ‘nonalcoholic fatty liver’ OR ‘non-alcoholic fatty liver’ OR ‘Nonalcoholic Steatohepatitis’ OR ‘Nonalcoholic Steatohepatitides’) AND (‘bicyclol’ OR ‘4,4’-bi-(1,3-benzodioxole)−5-carboxylic acid, 5’-(hydroxymethyl)−7,7’-dimethoxy, ‘methyl ester’ OR ‘6-methoxycarbonyl-6-hydroxymethyl-2,3,2’,3’-bis(methyleneedioxy)−4,4’-’dimethoxybiphenyl’) without other restrictions (online supplemental methods). Additional studies were hand-searched in Google Scholar and the reference lists of relevant articles.

Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) Randomised controlled trials (RCTs); (2) Male and female patients diagnosed with NAFLD complicated with or without T2DM according to the corresponding guidelines; (3) An average baseline ALT level greater than 90 U/L (2–3 times the upper limit of normal values),\textsuperscript{24} while a TG level ranging from 2.5 mmol/L to 5 mmol/L; and (4) Articles published in the English or Chinese language. The exclusion criteria were (1) Non-clinical studies, non-RCTs; (2) Studies examining patients with liver injury induced by drugs, viruses, alcohol, autoimmunity, primary biliary cholangitis, liver decompensation, malignancy or genetics; (3) Studies enrolling fewer than 20 subjects in each group, or the treatment time of less than 4 weeks; and (4) Studies without sufficient experimental data, such as case reports, reviews, conference abstracts, or a lack of sufficient biochemical indicators.

Intervention measures
The bicyclol monotherapy group (experimental group) was compared with groups treated with a lifestyle intervention (LSI) or another drug as a monotherapy (control group). Bicyclol combined with another medical treatment (experimental group) was compared with the corresponding medicine (control group). Other potential factors, such as LSIs were required to be consistent between the two groups.

Outcome indicators
Liver function indicators (ALT, AST and TBIL levels) and blood lipid parameters (TG and TC levels) were recorded. Adverse events, the anthropometric parameter body mass index (BMI), and the total effective rate, which was defined as the ratio of participants who have achieved significant decreases in blood biomarker levels (the decreased level of TC >10% and TG >20%) and parameter of liver fat reduction under B-model ultrasonography among the included participants in the corresponding studies, were also analysed.

Data extraction and quality assessment
The outcome indicators from all included studies were independently extracted and checked by two authors (HL and NNL) to guarantee the accuracy of the data. The quality of RCTs, which was assigned as a ‘high risk’, ‘low risk’ or ‘some concerns’ for each item, was also assessed independently by
two reviewers using the revised Cochrane risk of bias tool. Any discrepancies were resolved through discussion.

Data analysis
Review Manager V.5.3 software was used to analyse the data. OR and pooled mean difference (MD) with the corresponding 95% CI were estimated for binary outcomes and continuous outcomes, respectively. Heterogeneities were evaluated using the $\chi^2$ and I$^2$ statistics. When the outcome was homogeneous ($I^2<50\%$ and $P>0.10$), the fixed-effects model was used, and the random-effects model was used when the outcome was considered heterogeneous ($50\% \leq I^2 < 75\%$). When significant heterogeneity was observed (up to 75%), a subgroup analysis was conducted according to bicyclol monotherapy and combination therapy, and if the $I^2$ of the subgroup was still over 75%, descriptive results were provided without pooling estimates. The statistical significance of differences between the experimental and control groups was set at $P<0.05$. Publication bias was assessed only for comparisons with at least five studies using the funnel plot and its symmetry was evaluated using Egger’s regression tests through Stata V.12.0 software. Significant publication bias was defined as $p<0.10$. Grading of evidence for the key comparisons was performed using the approach described by the Grading of Recommendations, Assessment, Development and Evaluation working group.

Patient and public involvement
Patients and the public were not involved in this review.

RESULTS
Study selection
The whole flow chart of the data selection process is presented in figure 1. Initially, 166 records were searched out, and 94 records were retained after duplicate exclusion. We then achieved 34 studies after screening the title and abstract, in which reviews, case reports, animal experiments, and studies with incongruent intervention measures and research orientation were excluded. After screening the full text, we excluded studies without appropriate samples, biochemical indicators, and baseline ALT and TG levels. One irrelevant study, which included patients with alcoholic fatty liver, was also excluded. Finally, 12 studies published in Chinese were included.

Characteristics, quality evaluation and publication bias of the included studies
The characteristics of the included studies are presented in table 1. All the studies were conducted in China and published from 2005 to 2017, and the sample size ranged from 50 to 152 (median of 81). The total sample size is 1008 with 523 patients in the treatment group and 485 participants in the control group. The baseline values of patient outcome indicators were not different between the two groups.

The quality assessment of the included studies is shown in figure 2 according to the most recently revised Cochrane risk of bias tool (online supplemental table S1), in which one study applied the random number table, and other studies used randomisation but did not provide detailed methods. None of the studies reported the blinding condition or the plan of allocation and concealment. Additionally, all the studies had provided complete outcome data, without other predictable sources of bias.

The Egger’s tests of funnel plots (online supplemental figure S1) for primary outcomes did not reveal significant publication bias among the blood biomarkers of AST (8 studies, $p=0.964$), TC (11 studies, $p=0.567$) and TBIL (6...
| Study | Sample size | Intervention | Control | Dose of bicyclol | Duration | Outcomes | Adverse events |
|-------|-------------|--------------|---------|-----------------|----------|----------|----------------|
| Liao  | 30          | Bicyclol     | Vitamin C | 50 mg, three times a day | 12 weeks | ①③④⑤⑦⑧ | None           |
| Li     | 45          | Bicyclol     | UDCA    | 25-50 mg, three times a day | 24 weeks | ④⑥⑦⑧ | –              |
| Zhu    | 36          | Bicyclol     | Silymarin | 25-50 mg, three times a day | 24 weeks | ①④⑥⑦⑧ | –              |
| Yan    | 30          | Bicyclol     | DGEC    | 50 mg, three times a day | 4 weeks   | ④⑤⑦⑧ | None           |
| Zhang  | 60          | Bicyclol     | LSI     | 25 mg, three times a day | 24 weeks | ②④⑤⑦⑧ | –              |
| Gao    | 25          | Bicyclol+PPC | PPC     | 25-50 mg, two times per day | 6 months | ②④⑤⑦⑧ | None           |
| Ding   | 42          | Bicyclol+PPC | PPC     | 25-50 mg, two times per day | 6 months | ②④⑤⑦⑧ | Weight loss     |
| He     | 47          | Bicyclol+PPC | PPC     | 25-50 mg, three times a day | 6 months | ②④⑤⑦⑧ | None           |
| Li     | 50          | Bicyclol+metformin | Metformin | 25 mg, two times per day | 6 months | ②④⑤⑦⑧ | None           |
| Zhang  | 42          | Bicyclol+metformin | Metformin | 25-50 mg, two times per day | 6 months | ②④⑤⑦⑧ | None           |
| Sun    | 76          | Bicyclol+metformin | Metformin | 25 mg, two times per day | 6 months | ②④⑤⑦⑧ | None           |
| Guan   | 40          | Bicyclol+silibinin | Silibinin | 25 mg, two times per day | 6 months | ②④⑤⑦⑧ | None           |

① Total effective rate; ② BMI; ③ Adverse events; ④ ALT; ⑤ AST; ⑥ TBIL; ⑦ TG; ⑧ TC.

ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; DGEC, diammonium glycyrrhizinate enteric-coated capsule; LSI, lifestyle intervention; PPC, polyene phosphatidylcholine; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride; UDCA, ursodeoxycholic acid.
studies, p=0.485). However, ALT (12 studies, p=0.027) and TG (12 studies, p=0.004) showed significant publication bias. We speculated that the heterogeneity in the studies was the main determining factor, and a subgroup analysis was conducted.

Effect and safety of the bicyclol intervention for patients with NAFLD

The therapeutic effect and safety of bicyclol for NAFLD were first evaluated. As shown in figure 3, changes in BMI and the total effective rate at improving fatty liver indicated no heterogeneity, with I² of 0%, p=0.75, and I² of 42%, p=0.18, respectively. Two hundred and five patients in three studies were included in the analysis of the total effective rate, while 456 patients in four studies were included in the BMI analysis. The fixed-effects model revealed an increased total effective rate (total effective rate: OR=4.49; 95% CI 2.02 to 9.95; p=0.0002) but no significant effect on BMI (BMI: MD = −0.68; 95% CI −1.37 to 0.02; p=0.06) in the bicyclol group compared with the control group. No gastrointestinal adverse events, such as nausea, vomiting and diarrhoea, or headache were reported in the bicyclol treatment group in the included studies (table 1).

Effect of bicyclol on liver function biomarkers in patients with NAFLD

Serum ALT levels were reported in 12 studies. These trials involved 1008 patients, with 523 patients in the treatment group and 485 patients in the control group. A high level of statistical heterogeneity for ALT levels was observed, with I² of 95% and p<0.00001. Therefore, we further divided these studies into a bicyclol monotherapy subgroup and bicyclol combination treatment subgroup according to the drug regimen used in the experimental group. ALT levels in the bicyclol monotherapy subgroup, which were analysed using a random-effects model, were significantly decreased compared with those of the corresponding control group (ALT U/L: MD = −34.07; 95% CI −36.70 to −31.43; p<0.00001). However, significant heterogeneity was observed in the bicyclol combination subgroup with I² of 95% and p<0.00001. Therefore, we performed a descriptive analysis and showed that bicyclol was more likely to decrease the levels of ALT in all seven studies when administered in combination with other drugs (figure 4A).

Serum AST levels were recorded in eight trials covering 658 patients, including 335 and 323 participants in the treatment and control groups, respectively. Heterogeneity
was observed for AST levels, with $I^2$ of 74% (figure 4B). The random-effects model demonstrated that the reduction of AST levels was significant in patients with NAFLD treated by bicyclol as a monotherapy and combination therapy (AST U/L: MD = $-15.20$; 95% CI $-20.51$ to $-9.90$; $p <0.00001$).

Serum TBIL levels were detected in six trials, involving 472 participants, with 255 and 217 patients in the treatment and control groups, respectively (figure 4C). There was excellent homogeneity among the six studies, with $I^2 = 0\%$ and $p =0.60$, and the fixed-effects model indicated that bicyclol significantly decreased the TBIL level in patients with NAFLD (TBIL μmol/L: MD = $-1.72$; 95% CI $-2.72$ to $-0.72$; $p =0.0008$).

**Effect of bicyclol on blood lipid biomarkers in patients with NAFLD**

Twelve studies reported the TG levels. These trials involved 1008 patients, with 523 patients in the treatment groups and 485 patients in the control groups. A high level of statistical heterogeneity was observed for TG levels, with $I^2$ of 90% and $p<0.00001$, and thus the subgroup analysis was conducted. The bicyclol combination subgroup did not display heterogeneity, with $I^2 = 0\%$ and $p =0.89$, and it significantly decreased the TG level in patients with NAFLD compared with patients receiving monotherapy with other drugs, which was analysed by a random-effects model (TG mmol/L: MD = $-0.39$; 95% CI $-0.70$ to $-0.34$; $p<0.00001$). Substantial heterogeneity was observed in the bicyclol monotherapy subgroup, with $I^2$ of 95% and $p<0.00001$.

The descriptive analysis showed that bicyclol monotherapy was more likely to decrease the levels of TG in all the five monotherapy studies (figure 5A).

Eleven studies reported the TC levels. These trials involved 958 patients, with 498 and 460 patients in the treatment and control groups, respectively. The $I^2$ of TC was 67%, and therefore, the random-effects model was conducted and showed that the reduction of TC levels in patients with NAFLD treated by bicyclol was significant (TC mmol/L: MD = $-0.52$; 95% CI $-0.70$ to $-0.34$; $p<0.00001$) (figure 5B).

**Grading the evidence**

The evidence for the key outcomes was graded based on the limitations of precision, publication bias, risk of bias and heterogeneity. The quality of evidence was either low or very low (table 2).

**DISCUSSION**

By performing a meta-analysis of 12 Chinese studies including 1008 patients, this review provided evidence that bicyclol, regardless of its application as a monotherapy or in combination with other drugs, exerts a positive effect on improving liver function (ALT, AST and TBIL) and blood lipid levels (TG and TC). Although the bicyclol combination treatment for ALT levels and monotherapy for TG levels showed considerable heterogeneity, each trial among the included studies reported promising therapeutic effects on abnormal blood biomarker levels.
In the clinic, bicyclol is recommended for oral administration for up to 6 months. Although adverse events, such as gastrointestinal intolerance were sporadically reported in the control group in this meta-analysis (Table 1), these mild discomforts were not reported in the bicyclol-treated group, which agreed with the extremely mild and rare incidence of adverse reactions observed in long-term clinical practice. Moreover, only three of the included studies concluded that the bicyclol intervention produced a higher total effective rate for fatty liver, which was mainly based on blood biomarker levels and B-model ultrasonography results. We thus evaluated the liver function and blood lipid biomarkers as the primary outcome, although liver histology is the gold standard and MRI has higher accuracy for assessing fatty liver.

The pathogenesis of NAFLD is complex and is strongly associated (over 76%) with T2DM; 41-43 patients with or without T2DM were thus included in this review. Additionally, the course of the disease varied among the included studies, and some studies did not report the patient’s medical history; therefore, we limited the baseline ALT and TG levels to ensure the consistency of the included patients as much as possible. We also defined the treatment duration as at least 4 weeks, because NAFLD is a chronic disease and bicyclol is suitable for long-term oral administration. Although the use of bicyclol to treat NAFLD is an off-label use, the Chinese guidelines of prevention and treatment for NAFLD updated in 2018 recommend that hepatoprotectants are potentially complementary treatment measures for patients...
A. TG (mmol/L)

| Study or Subgroup | Experimental | Control | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|---------|-----------------------------------|
|                   | Mean SD Total| Mean SD Total| Weight |                          |
| Bicyclol monotherapy |              |          |        |                          |
| Liang 2007        | 1.7 0.2 45   | 2.2 0.1 38 | 10.4%  | -0.50 [-0.57, -0.43] |
| Liao 2011         | 2.04 0.29 30 | 2.95 0.4 30 | 8.9%   | -0.91 [-1.09, -0.73] |
| Yan 2017          | 1.7 0.3 30   | 1.9 0.4 30 | 8.9%   | -0.20 [-0.38, -0.02] |
| Zhang 2012        | 1.9 0.3 60   | 2.2 0.5 60 | 9.4%   | -0.30 [-0.45, -0.15] |
| Zhu 2005          | 1.58 0.1 36  | 2.38 0.2 29 | 10.3%  | -0.80 [-0.88, -0.72] |
| Subtotal (95% CI) | 201          | 187      | 47.8%  | -0.54 [-0.77, -0.32] |

Heterogeneity: Tau² = 0.06; Ch² = 79.27, df = 4 (P < 0.00001); I² = 95%
Test for overall effect: Z = 4.81 (P < 0.00001)

Bicyclol combination

| Study or Subgroup | Experimental | Control | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|---------|-----------------------------------|
|                   | Mean SD Total| Mean SD Total| Weight |                          |
| Ding 2009         | 2.69 0.62 42 | 3.07 0.86 30 | 5.8%   | -0.38 [-0.74, -0.02] |
| Gao 2011          | 2.65 0.54 25 | 3.21 0.88 25 | 5.2%   | -0.56 [-0.96, -0.16] |
| Guan 2013         | 2.4 1 40    | 2.6 1.1 40 | 4.5%   | -0.20 [-0.66, 0.26] |
| He 2011           | 1.7 0.2 47  | 2.1 0.2 35 | 10.2%  | -0.40 [-0.49, -0.31] |
| Liu 2014          | 1.35 0.44 50 | 1.75 0.47 50 | 9.8%   | -0.40 [-0.58, -0.22] |
| Sun 2015          | 1.34 0.43 76 | 1.74 0.46 76 | 9.5%   | -0.40 [-0.54, -0.26] |
| Zhang 2011        | 1.38 0.45 42 | 1.66 0.61 42 | 8.0%   | -0.28 [-0.51, -0.05] |
| Subtotal (95% CI) | 322          | 298      | 52.2%  | -0.39 [-0.45, -0.33] |

Heterogeneity: Tau² = 0.00; Ch² = 2.30, df = 6 (P = 0.69); I² = 0%
Test for overall effect: Z = 12.08 (P < 0.00001)

Total (95% CI)

| Study or Subgroup | Experimental | Control | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|---------|-----------------------------------|
|                   | Mean SD Total| Mean SD Total| Weight |                          |
|                   |              |          |        |                          |
| Total             | 523          | 485     | 100.0% | -0.46 [-0.59, -0.33] |

Test for overall effect: Z = 6.95 (P < 0.00001)
Test for subgroup differences: Ch² = 105.58, df = 11 (P < 0.00001); I² = 90%

B. TC (mmol/L)

| Study or Subgroup | Experimental | Control | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|---------|-----------------------------------|
|                   | Mean SD Total| Mean SD Total| Weight |                          |
| Ding 2009         | 4.12 0.44 42 | 4.7 0.51 30 | 11.5%  | -0.58 [-0.81, -0.35] |
| Guan 2013         | 4.6 1.5 40   | 4.9 1.3 40 | 5.3%   | -0.30 [-0.92, 0.32] |
| He 2011           | 4.3 0.7 47   | 4.5 0.7 35 | 10.0%  | -0.20 [-0.51, 0.11] |
| Li 2014           | 3.24 0.89 50 | 4.12 1.21 50 | 8.0%   | -0.88 [-1.30, -0.46] |
| Liang 2007        | 4.3 0.7 45   | 4.5 0.8 36 | 9.6%   | -0.20 [-0.53, -0.13] |
| Liu 2014          | 6.04 0.69 50 | 6.75 0.47 50 | 9.8%   | -0.81 [-1.13, -0.49] |
| Sun 2015          | 3.13 0.78 76 | 4.01 1.18 76 | 9.8%   | -0.88 [-1.20, -0.56] |
| Yan 2017          | 5.5 0.7 30   | 5.9 0.6 30 | 9.6%   | -0.40 [-0.73, -0.07] |
| Zhang 2011        | 3.17 0.97 42 | 4.24 1.25 42 | 7.1%   | -1.07 [-1.55, -0.59] |
| Zhang 2012        | 4.3 0.8 60   | 4.6 0.9 60 | 10.0%  | -0.30 [-0.60, 0.00] |
| Zhu 2005          | 4.2 0.6 36   | 4.4 0.8 29 | 9.2%   | -0.20 [-0.55, 0.15] |
| Subtotal (95% CI) | 498          | 460     | 100.0% | -0.52 [-0.70, -0.34] |

Heterogeneity: Tau² = 0.06; Ch² = 30.43, df = 10 (P = 0.0007); I² = 67%
Test for overall effect: Z = 5.68 (P < 0.00001)

**Figure 5** The effect of bicyclol on TG and TC levels in patients with NAFLD. Review Manager V.5.3 software was used to analyse the data. Mean difference (MD) with its 95% CI was estimated for continuous outcomes. Heterogeneities were evaluated using the \( \chi^2 \) and I² statistics. The TG parameter was significantly heterogeneous (I²≥75%) and subgroup analysis was conducted (A); the TC parameter was considered heterogeneous (50% ≤ I²<75%) and the random-effects model was used (B). p<0.05 was considered as statistically different between the experimental and control groups. NAFLD, alcoholic fatty liver disease; TC, total cholesterol; TG, triglyceride.

with NASH with elevated aminotransferase levels or liver injury. Compared with the intervention in the control group, including lifestyle changes and other drug treatments, the alleviation of abnormal blood biomarker levels by bicyclol is evident and consistent with its clinical practice. Notably, subgroup analyses for ALT and TG levels, which were conducted when significant heterogeneity existed, also provided substantial evidence for its effect.

This review has to interpret the limitations of the low quality of the included studies, publication bias and low grading of evidence. All the included studies were conducted in China, and many of them did not provide a description of specific methods of blinding and random allocation concealments. In terms of the outcome indicators, most articles lacked information on the blood glucose levels and insulin resistance index, and thus the results of the meta-analysis merely provide the effect of bicyclol on liver function and blood lipid indicators. Though the biomarkers AST, TC and TBIL showed no publication bias, ALT and TG showed significant
publication bias. We speculated that the heterogeneity and language bias contributed to this publication bias, and subgroup analysis was conducted. Additionally, when the degree of heterogeneity was large, Egger’s tests did not have good properties. Similarly, the low grading of evidence was mainly derived from the publication bias, risk of bias and heterogeneity. Therefore, the results of the meta-analysis merely provide a reference based on the current evidence.

In conclusion, the present study presents the effectiveness of bicyclol monotherapy and/or combination therapy at ameliorating the altered liver function and blood lipid biomarkers in patients with NAFLD. This preliminary study predicts that bicyclol might be an alternative available drug to be explored for NAFLD therapy in the future. However, the conclusion also needs to be further verified in more well-designed and implemented studies.

Contributors Conceptualisation, analysis, writing original draft, visualisation: HL; Validation of data and analysis: N-NL; Supervision, validation and writing draft: Z-GP; Approval of final manuscript: all authors.

Funding This work was supported by CAMS Innovation Fund for Medical Sciences (2019-2M-1-001), National Natural Science Foundation, China (81621064), and National Mega-Project for ‘R&D for Innovative drugs’, Ministry of Science and Technology, China (2018ZX09711001-003-010).

Competing interests None declared

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use are not non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Hu Li http://orcid.org/0000-0002-7609-9399

REFERENCES
1 Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908–22.
2 Rosso N, Bellentani S. Nonalcoholic Fatty Liver Disease: A Wide Spectrum Disease. In: Radu-Ionita F, Pyrsopoulos N, Jinga M, et al., eds. Liver diseases. Springer, Cham, 2020.
3 Shi T, Wu L, Ma W, et al. Nonalcoholic fatty liver disease: pathogenesis and treatment in traditional Chinese medicine and Western medicine. Evid Based Complement Alternat Med 2020:2020:1–16.
4 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
5 Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–98.
